Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lepu Biopharma CoHKSE:02157 -2.92%44 PB Ratio is 5.48 as of Aug. 12, 2026, which is 22% below its 10-year median of 7.07. GuruFocus rates HKSE:02157 with a GF Score™ of 44/100 and a GF Value™ of HK$15.69 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,222 Biotechnology companies, Lepu Biopharma Co ranks worse than 71.6% on this metric.
The historical rank and industry rank for Lepu Biopharma Co's PB Ratio or its related term are showing as below:
HKSE:02157'
s PB Ratio Range Over the Past 10 Years
Min: 4.04 Med: 7.07 Max: 23.19
Current: 5.47
During the past 7 years, Lepu Biopharma Co's highest PB Ratio was 23.19. The lowest was 4.04. And the median was 7.07.
HKSE:02157's PB Ratio is ranked worse than 71.6% of 1222
companies
in the Biotechnology industry
Industry Median: 2.92
vs HKSE:02157: 5.47
During the past 12 months, Lepu Biopharma Co's average Book Value Per Share Growth Rate was 93.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 11.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -5.90% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Lepu Biopharma Co was 11.90% per year. The lowest was -17.50% per year. And the median was -10.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Lepu Biopharma Co PB Ratio Related Terms
Lepu Biopharma Co PB Ratio Historical Data
* Premium members only.
The historical data trend for Lepu Biopharma Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02157 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Lepu Biopharma Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lepu Biopharma Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lepu Biopharma Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lepu Biopharma Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Lepu Biopharma Co (HKSE:02157) has a PB Ratio of 5.48 as of Aug. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lepu Biopharma Co and its competitors. This is 22% below median its historical median of 7.07. Over the past decade, Lepu Biopharma Co's PB Ratio has ranged from 4.04 to 23.19. According to the industry distribution chart, Lepu Biopharma Co ranks #875 out of 1222 companies in the Biotechnology industry, placing it in the top 71.6%.
Is Lepu Biopharma Co's PB Ratio too high?
Lepu Biopharma Co's current PB Ratio of 5.48 is 22% below median its 10-year median of 7.07. Over the past 10 years, this metric has ranged from a low of 4.04 to a high of 23.19. The Biotechnology industry median PB Ratio is 2.92. Lepu Biopharma Co's value of 5.48 is 87.7% above this industry median. Based on the distribution chart, Lepu Biopharma Co ranks #875 out of 1222 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lepu Biopharma Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lepu Biopharma Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lepu Biopharma Co ranks #875 out of 1222 companies for PB Ratio. This places Lepu Biopharma Co in the lower half of its industry. The industry median PB Ratio is 2.92. Lepu Biopharma Co's value of 5.48 is 87.7% above this benchmark. Historically, Lepu Biopharma Co's own PB Ratio has ranged from 4.04 to 23.19 over the past decade. While the company's 10-year median is 7.07 vs. the industry median of 2.92, Lepu Biopharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,222 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lepu Biopharma Co's current PB Ratio of 5.48 is 87.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lepu Biopharma Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lepu Biopharma Co's current PB Ratio is 5.48, which is 22% below median its own 10-year median of 7.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Biopharma Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Biopharma Co (HKSE:02157) is currently considered Possible Value Trap. The stock's GF Value™ is HK$15.69, compared to a current price of HK$4.65 — trading 70.4% below its estimated fair value. The current PB Ratio is 5.48, which is 22% below median its 10-year median of 7.07 and 87.7% above the Biotechnology industry median of 2.92. Lepu Biopharma Co's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Lepu Biopharma Co (HKSE:02157), the current PB Ratio is 5.48 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Biopharma Co (HKSE:02157) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Biopharma Co stock appears to be undervalued.
The current stock price of HK$4.65 is trading 70.4% below its estimated GF Value™ of HK$15.69.
GuruFocus considers Lepu Biopharma Co to be Possible Value Trap.
Key valuation signals for HKSE:02157:
PB Ratio: 5.48 (22% below median its 10-year median of 7.07)
GF Value™: HK$15.69 vs. price of HK$4.65 (70.4% below fair value)
Industry Position: 87.7% above the Biotechnology median (#875 of 1222)
No single metric tells the full story. See the HKSE:02157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score
Get the complete analysis for HKSE:02157
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02157 has been successfully added to your 
